作为腹腔大动脉动脉瘤的药物标,蛋白转化酶亚提利辛/凯类型9作为药物标
Jonathan Golledge1,2,3, Hong S Lu4,5, Sonia Shah6
1Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University.
Current opinion in lipidology
|July 25, 2024
概括
抑制蛋白转化酶亚提利辛/凯辛9型 (PCSK9) 可能为腹腔大动脉动脉瘤 (AAA) 提供一种新的治疗方法. 抑制PCSK9可能会限制AAA的生长并降低心血管风险,这需要进一步的临床试验.
科学领域:
- 心血管研究研究心血管研究
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 腹腔大动脉瘤 (AAA) 的生长目前缺乏向药物治疗.
- 增加的LDL和非HDL胆固醇与AAA形成有因果关系.
- 在人类AAA组织中,PCSK9的升级调节.
研究的目的:
- 审查PCSK9抑制作为限制AAA生长的潜在治疗点的证据.
- 探索PCSK9在AAA病原和心血管风险降低中的作用.
主要方法:
- 关于将胆固醇水平与AAA联系起来的孟德尔随机化研究的综述.
- 在人类AAA样本中研究PCSK9表达的研究分析.
- 对动物模型的检查 (例如,注射 angiotensin II 的小鼠) 评估 PCSK9 对大动脉扩张的影响.
主要成果:
- 门德尔随机化支持AAA中高LDL和非HDL胆固醇的因果作用.
- 在人类AAA中,PCSK9的升高调节,并在小鼠模型中促进大动脉扩张.
- 影响PCSK9的突变与AAA风险增加有关;PCSK9的抑制可能会减少心血管事件.
结论:
- PCSK9抑制剂显示为AAA的新疗法,可能限制生长和心血管风险.
- 需要进一步的大规模,跨国随机对照试验来验证PCSK9抑制对AAA治疗的有效性.
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Antihypertensive Drugs: Vasodilators
495
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
495
Clot Retraction and Fibrinolysis
5.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.3K


